Abbvie humira patent cliff?

Short answer: Yes—the “Humira patent cliff” is about the expiry of key patents on adalimumab (Humira) and the resulting entry of biosimilars. The cliff isn’t a single date, but a regional process: patents expire at different times in different places, and biosimilars can enter only after those expiries (and after legal/regulatory hurdles are cleared).

What that means in practice
- Humira’s revenue protection depended on a bundle of patent protections (composition patents, process/formulation patents, method-of-use patents, regulatory exclusivities, etc.). As those protections expired or narrowed, biosimilars began to enter markets.
- The US timeline has been the most talked-about part of the cliff in recent years, with the main composition patent expiring and biosimilars launching in 2023–2024 after settlements and court rulings. Other US patent opportunities (related to formulations, methods, or filing exclusivities) also affected when certain biosimilars could launch.
- Europe saw earlier and more extensive biosimilar competition, with several Humira biosimilars marketed there starting around 2018–2020 and continuing to erode Humira’s price and share over time.
- Globally, timelines vary by country and by which patents were still in force, but the general pattern is that Humira has faced increasing biosimilar competition since the late 2010s and into the 2020s.

Business impact and AbbVie’s response
- Revenue from Humira has faced pressure as biosimilars gain share, especially in markets where patent protection has ended.
- AbbVie has been offsetting through growth in newer drugs (Rinvoq, Skyrizi) and ongoing price/rebate management, cost controls, and market strategy.
- The market is still watching for remaining patent expiries on ancillary patents and any new regulatory data protections, which could influence the pace of biosimilar entry in different regions.

If you want: I can provide a region-by-region timeline with approximate expiry dates and notable biosimilar launches, or pull up recent investor notes and regulatory filings for precise dates. Which region or level of detail would you prefer?